News
FDA clears Roche’s Alecensa for adjuvant use in NSCLC
Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA for adjuvant use after surgery in early-stage,
Digital
Sponsored
Innovation as Strategy: Enabling life sciences of the future
Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.
R&D
The many trends reshaping clinical trials: An interview with...
Over the last five years, a confluence of trends have combined to reshape the reality of clinical research. COVID-19 pushed decentralised trials into the mainstream.
Sales & Marketing
Sponsored
How doctors are interacting with content in 10 data trends
It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.
Oncology
Sponsored
Patient Centricity to Integration: Enhancing Cancer Outcomes
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
R&D
Partner Content
FT US PHARMA AND BIOTECH SUMMIT
2024 is a pivotal year for the US healthcare sector.
R&D
Partner Content
3rd HF Drug Discovery & Development Summit
The Industry’s Only Definitive Forum for Preclinical Heart Failure Drug Development
Category :
System
/
